<code id='2634D7FA29'></code><style id='2634D7FA29'></style>
    • <acronym id='2634D7FA29'></acronym>
      <center id='2634D7FA29'><center id='2634D7FA29'><tfoot id='2634D7FA29'></tfoot></center><abbr id='2634D7FA29'><dir id='2634D7FA29'><tfoot id='2634D7FA29'></tfoot><noframes id='2634D7FA29'>

    • <optgroup id='2634D7FA29'><strike id='2634D7FA29'><sup id='2634D7FA29'></sup></strike><code id='2634D7FA29'></code></optgroup>
        1. <b id='2634D7FA29'><label id='2634D7FA29'><select id='2634D7FA29'><dt id='2634D7FA29'><span id='2634D7FA29'></span></dt></select></label></b><u id='2634D7FA29'></u>
          <i id='2634D7FA29'><strike id='2634D7FA29'><tt id='2634D7FA29'><pre id='2634D7FA29'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:38
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In